Court Upholds Norvasc Patent
This article was originally published in The Pink Sheet Daily
Executive Summary
Apotex will be prohibited from launching a generic of amlodipine until September 2007, according to a Jan. 18 ruling out of Chicago federal court
You may also be interested in...
Pfizer’s Norvasc Does Not Infringe Synthon Patent, Court Finds
The company’s revenues stemming from its blockbuster hypertension treatment remain safe after Synthon had challenged its manufacturing process.
Pfizer’s Norvasc Does Not Infringe Synthon Patent, Court Finds
The company’s revenues stemming from its blockbuster hypertension treatment remain safe after Synthon had challenged its manufacturing process.
Mylan Granted 180-Day Exclusivity On Norvasc
Mylan holds 180-day exclusivity on all three doses of Pfizer's Norvasc following FDA's confirmation that the generic firm was first-to-file on the 2.5 mg, 5 mg and 10 mg amlodipine doses, the company announced Oct. 4